AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article favors AbbVie over CRISPR Therapeutics for 2026, citing AbbVie's $61.2B FY2025 revenue (+8.6%), $17.8B free cash flow, expanding Skyrizi and Rinvoq franchises, and dividend support. CRISPR generated only $3.5M of FY2025 revenue, down 90% year over year, and posted a $581.6M net loss with $345.9M of free-cash-flow burn, despite Casgevy's commercial progress and expanded pediatric FDA approval. AbbVie faces Humira biosimilar competition, pricing pressure and a weaker balance sheet, while CRISPR remains highly dependent on Vertex and long-term execution of unproven gene-editing programs.

Analysis

ABBV’s rerating path depends less on legacy-product erosion and more on whether its growth immunology franchise can sustain premium pricing as payer leverage rises. The key second-order beneficiary of continued high-cost specialty-drug volume is MCK/COR, whose distribution economics and manufacturer-service revenues are less exposed to single-product patent cliffs than ABBV’s branded gross profit. ABBV’s leverage is manageable only while conversion of earnings to cash remains intact; any immunology volume miss would simultaneously pressure the equity multiple and reduce balance-sheet flexibility for buybacks and dividend growth.

CRSP is not a clean gene-editing beta: its value is a long-duration, partner-controlled option on treatment-center activation, reimbursement, manufacturing throughput, and durable safety—not merely regulatory labels. Near-term sales milestones can create sharp upside, but a small absolute revenue base means commercial traction must exceed operating burn before the stock can graduate from clinical-asset valuation to platform valuation. The article’s characterization of commercialization should be independently checked against Vertex’s reported product revenue, net-profit sharing, and launch metrics; the referenced partner ticker is incorrect (Vertex is VRTX, while VERX is Veeva).

Consensus likely overstates ABBV’s defensive quality and understates CRSP’s financing advantage. ABBV can underperform defensives in a reimbursement or IRA-driven pricing shock, whereas CRSP’s cash runway limits dilution risk over the next 12-24 months if burn remains near current levels. Conversely, CRSP is vulnerable to a disproportionate drawdown if uptake fails to inflect over the next two quarterly updates because the remaining pipeline does not yet provide diversified cash-flow support.

Key Decisions for Investors

• Maintain a core long ABBV versus a short basket of slower-growth large pharma (PFE or BMY), sized for a 6-12 month horizon. The thesis is superior franchise mix and cash conversion; exit if management cuts immunology growth guidance or if quarterly net price/volume trends imply payer resistance. Do not add solely on dividend yield.
• Use CRSP only as a small, catalyst-defined long through the next 1-3 quarterly commercialization disclosures, preferably paired short VRTX only after confirming CRSP’s contractual profit-share sensitivity. Require evidence of rising treated patients, center activation, and improving net economics; absent those data, this is a watch item rather than a standalone recommendation.
• Long MCK or COR on weakness as a lower-volatility way to express resilient specialty-pharma volumes over 6-18 months. Risk is policy-driven distribution-margin scrutiny or a broad branded-drug volume contraction; monitor manufacturer-services growth and working-capital turns.
• Avoid VERX as a proxy for CRSP’s partner economics; validate all launch and profit-share data using VRTX filings before trading the gene-editing thesis.